Alzamend Neuro is a clinical stage drug developer in Atlanta working on treatments for Alzheimer's and other brain disorders. ALZN reports earnings on Tue, Dec 8, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 19 | Ascendiant Capital | Maintained | Buy |
Seasonality
How ALZN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in ALZN in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALZN is in one of them and how their past ALZN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ALZN in an article yet. Here's the latest on the wider market.
About Alzamend Neuro
Alzamend Neuro is a clinical stage drug developer based in Atlanta, Georgia, focused on brain disorders. It is working on treatments for Alzheimer's disease, bipolar disorder, major depressive disorder and post traumatic stress disorder. Its lead candidate, AL001, is a form of lithium designed to treat these conditions, and it is in human clinical trials. Its target patients are people living with these illnesses.
- Headquarters
- Atlanta, GA